Navigation Links
Gene Network Sciences Awarded Patent Covering REFS(TM) Platform
Date:5/4/2009

CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has been awarded U.S. Patent No. 7,512,497, entitled "Systems and Methods for Inferring Biological Networks." The patent covers GNS's core model learning and simulation platform, REFS(TM) (Reverse Engineering and Forward Simulation).

GNS has deployed the REFS(TM) platform in several collaborations with pharmaceutical and biotechnology companies and academic and clinical institutions in diseases areas such as oncology, rheumatoid arthritis, cardiovascular and metabolic disease, and Alzheimer's disease. The REFS(TM) platform, which is run on supercomputers, enables the rapid extraction of actionable, patient-specific knowledge directly from experimental and clinical data.

"We have now extended our patent portfolio beyond our previous issued patents covering an ultra-efficient language to model known biology and the simulation of known pathways, to the fully data-driven inference and simulation of novel biology," said Tom Neyarapally, Senior Vice President of Corporate Development for GNS. "GNS now has broad intellectual property coverage across our modeling and simulation activities."

GNS has several other pending patent applications addressing the REFS(TM) platform and its use in areas of application in biological systems and areas outside of biology such as quantitative finance, online advertising, and natural resource exploration, as well as applications covering drug targets, biomarkers, and diagnostic markers discovered using the REFS(TM) platform.

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthy Living Network Announces Launch of New Blood Sugar Web Site
2. Blue Cross Blue Shield of Michigan and Blue Care Network Launch Web Sites to Help Chrysler Members Easily Find Information on Their Health Care
3. Technologically Advanced Digital Handheld Device Positions Network Global Logistics as Technology Leader in Last Mile Delivery Solutions
4. Healthy Living Network Announces Launch of New Supplement Information Web Site
5. Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB
6. Diversified Agency Services Network Launches TogoRun(TM), A New Global Healthcare Communications Agency
7. Insurers Administrative Corporation Joins the Availity Network
8. Anthem Blue Cross and Blue Shield and Middlesex Hospital Renew Network Agreement
9. Health Caring - A Network of Strength
10. Family Healthcare Network Selects InteGreat EHR for Deployment of Browser-Based EHR
11. Agito Networks Named to the First Annual InformationWeek Startup 50 Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... Yisrayl ... that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding ... this current generation. He explains that the Bible details the current times so ...
(Date:2/24/2017)... Emeryville, CA (PRWEB) , ... February 24, 2017 ... ... Esparza for qualifying into the Senior International Elite division on February 12th. ... All Around divisions at the elite qualifier competition held in Las Vegas, Nevada. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a ... today announced that Premier Research, a leading clinical development service provider, has selected ... becoming increasingly complex, due in part to an array of circumstances including the ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize ... der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced that it will release fourth quarter and ... March 2nd, 2017. AcelRx management will host an ... (1:30 p.m. Pacific Time) on March 2 nd ...
(Date:2/23/2017)... , February 23, 2017 According ... by Product (X-ray Imaging Digital, Analog), MRI (Closed, Open), ... MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) - ... studies the global market over the forecast period of ... ~USD 36.43 Billion by 2021, at a CAGR of ...
Breaking Medicine Technology: